• The partnership will address the false and misleading promotion about biosimilars within their respective authorities and prevent anti-competitive behavior. Additionally- the agencies will collaborate with participants from industry- academia and government agencies for discussing issues related to competition in the biologics market
• The agencies will collaboratively exchange the information for suitable practices in preventing the activities that the biosimilar is needed for testing. Also- the FTC will review the patent settlements for preventing antitrust violations
•  The FDA’s BAP outlines four strategies for accelerating the biosimilar competition- including supporting market competition and providing direction to industry for the development of promotional materials for medical products. The FDA and FTC will uphold a public workshop FDA/FTC Workshop on a Competitive Marketplace for Biosimilars on Mar 9- 2020 at FDA’s White Oak Campus in Silver Spring- Maryland

Click here to read full press release/ article | Ref: The US FDA | Image: Twitter